Popular Stories
Avise Analytics | THE FUTURE OF HEPATITIS-B TREATMENT [ MUST WATCH ]
Hepatitis B Virus Infection affects an estimated 257 million people worldwide and causes 780,000 deaths per year as per a report by World Health Organisation.
Arbutus Biopharma, ABUS, Biotech, Bio-pharmaceutical, ContraVir Pharmaceuticals, NASDAQ, CTRV, Vical Incorporated, VICL, Dicerna Pharmaceuticals, NASDAQ, DRNA, Arrowhead Pharmaceuticals, NASDAQ, ARWR,
17751
post-template-default,single,single-post,postid-17751,single-format-standard,ajax_fade,page_not_loaded,,side_area_uncovered_from_content,qode-child-theme-ver-1.0.0,qode-theme-ver-7.4,wpb-js-composer js-comp-ver-5.0.1,vc_responsive

THE FUTURE OF HEPATITIS-B TREATMENT [ MUST WATCH ]

1Comment
  • Anton
    Posted at 00:51h, 20 March Reply

    After my Hepatitis B diagnosis, I started Lamivudine (Epivir-HBV) which initially suppressed the virus. After a couple of years the virus became resistant, so i started on HB-V Formula treatment from xxxxxx, this natural HB-V Formula treatment totally reversed my hepatitis b virus. I did another blood test after the recommended treatment and i tested negative to the virus. This treatment is a breakthrough for all Hepatitis B virus carriers.

Post A Comment

WordPress Video Lightbox Plugin